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ABSTRACT 
The fullPIERS model is a risk prediction model developed to predict adverse maternal outcomes 
within 48 hours for women admitted with pre-eclampsia. External validation of the model is 
required before implementation for clinical use. We assessed the temporal and external validity 
of the fullPIERS model in high income settings using five cohorts collected between 2003 and 
2016, from tertiary hospitals in Canada, the United States of America, Finland and the United 
Kingdom. The cohorts were grouped into three datasets for assessing the primary external, and 
temporal validity, and broader transportability of the model. The predicted risks of developing an 
adverse maternal outcome were calculated using the model equation and model performance was 
evaluated based on discrimination, calibration, and stratification. Our study included a total of 
2,429 women, with an adverse maternal outcome rate of 6.7%, 6.6%, and 7.0% in the primary 
external, temporal, and combined (broader) validation cohorts, respectively. The model had good 
discrimination in all datasets: 0.81 (95%CI 0.75-0.86), 0.82 (95%CI 0.76-0.87), and 0.75 
(95%CI 0.71-0.80) for the primary external, temporal, and broader validation datasets, 
respectively. Calibration was best for the temporal cohort but poor in the broader validation 
dataset. The likelihood ratios estimated to rule in adverse maternal outcomes were high at a cut-
off of ≥30% in all datasets. The fullPIERS model is temporally and externally valid and will be 
useful in the management of women with pre-eclampsia in high income settings although model 
recalibration is required to improve performance, specifically in the broader healthcare settings.  
Key words: pregnancy hypertension, pre-eclampsia, prediction, maternal outcomes, prognosis, 
model validation  
  
 
INTRODUCTION 
Pre-eclampsia and other hypertensive disorders of pregnancy (HDPs) remain a significant cause 
of maternal and fetal morbidity and mortality, globally.1,2 Severe maternal morbidities resulting 
from pre-eclampsia include stroke, eclampsia and liver dysfunction.3 Presently, delivery is the 
only cure; however, this is not always the best option for the fetus if the delivery occurs 
preterm.1 While expectant management has been proposed as a means to achieve improved fetal 
survival, it is unclear for how long to delay delivery and how high the resultant risk is for the 
mother.4,5 Accurate prognosis in women with pre-eclampsia and other HDPs is necessary to 
support a practice of expectant management and guide clinical decisions for timing of delivery, 
administration of antenatal corticosteroids and magnesium sulphate, or transfer to a higher level 
of care.  
The fullPIERS (Pre-eclampsia Integrated Estimate of RiSk) model was developed to predict 
adverse maternal outcomes resulting from pre-eclampsia. The study’s primary adverse maternal 
outcome was defined as one or more of the pre-specified severe maternal complications, which 
included central nervous system (CNS), hepatic, renal, cardiovascular and respiratory outcomes, 
occurring within 48 hours of a woman’s admission for pre-eclampsia (full definitions listed in 
Table S1).6 The rationale behind the PIERS project was that correctly identifying an individual 
woman’s risk of complications before they happen would improve the clinician’s ability to 
counsel that woman on timing of delivery and use of other interventions and avoid those 
complications. The multivariable model was developed in 2010 using a cohort of 2023 women 
admitted in tertiary centres in high income countries (HICs) with a 5% rate of adverse maternal 
outcomes. All the participating hospitals had expectant management policies for pre-eclampsia. 
Six predictor variables were included in the model: gestational age, chest pain or dyspnoea, 
  
 
oxygen saturation (SpO2), platelet count, serum creatinine, and serum aspartate transaminase. 
The fullPIERS model was internally validated and had excellent discriminatory performance, 
with an area under the receiver-operating characteristic curve (AUROC) of 0.88 (95% 
confidence interval [CI], 0.84–0.92). The fullPIERS model equation is shown in Box 1. 
Although the model has promising predictive performance, temporal and external validation are 
necessary before it can be recommended for clinical use.7,8 Validation ascertains the accuracy of 
the model in the population that it was designed for based on discriminatory and calibration 
performance. Temporal validation is carried out in the same setting as the one used during model 
development but with more recent patients, thereby prospectively evaluating model performance. 
External validation involves assessments in a similar population to that used for model 
development in other settings. Geographical validation is a type of external validation that 
includes cases that have the same inclusion and exclusion criteria as the development setting.8,9 
Although there have been a few attempts to externally validate the fullPIERS model, none of the 
studies conducted have used a similar patient populations and healthcare settings as the 
development population. Differences include use of data from low-and-middle-income countries 
(LMIC)10,11 or using a subset (less than 34 weeks’ gestational age) or broader inclusion criteria 
for disease (all HDPs). In addition, inadequate sample size has been an issue limiting the 
conclusions that can be drawn from these studies.12 Using a sufficient sample size, we sought to 
assess geographic external- and temporal- validity of the fullPIERS model using datasets 
collected in high income countries with similar populations. 
 
 
Box 1: The fullPIERS Logistic Regression Equation for the prediction of adverse maternal 
outcomes from pre-eclampsia: logit(pi)=2·68+(–5·41×10–²; gestational age at 
eligibility)+1·23(chest pain or dyspnoea)+(–2·71×10–²; creatinine)+(2·07×10–¹; 
platelets)+(4·00×10–⁵; platelets²)+(1·01×10–²; aspartate trans aminase)+(–3·05×10–⁶; 
AST²)+(2·50×10–⁴; creatinine×platelet)+(–6·99×10–⁵; platelet×aspartate transaminase)+  
(–2·56×10–³; platelet×SpO2) 
  
 
METHODS 
Ethics 
This study was approved by the University of British Columbia ethics board (CREB no: H07-
02207). 
Study population 
Development cohort 
The fullPIERS model was developed using data collected from high-income countries: Australia, 
Canada, New Zealand and the United Kingdom (UK). Data were collected prospectively from 
2,023 women admitted to a participating tertiary level facility with pre-eclampsia from July, 
2008 to January 2011. Pre-eclampsia was defined as hypertension with proteinuria or 
hyperuricaemia, or HELLP (Haemolysis Elevated Liver enzymes Low Platelet count) 
syndrome.6 The study’s primary adverse maternal outcome was a pre-specified composite of 
severe maternal complications occurring within 48 hours of hospital admission. These outcomes 
were agreed upon using a Delphi consensus process prior to the model development study.6 A 
full list of the outcomes is listed in appendix S1 and a fullPIERS calculator online (https://pre-
empt.cfri.ca/monitoring/fullpiers ) and. Women were excluded from the cohort if they had 
already experienced an adverse maternal outcome before hospital admission and data collection 
or if they were admitted in spontaneous labour. Further details of the fullPIERS cohort have been 
described elsewhere.6 
 
 
  
 
Temporal and External Validation datasets 
We identified five cohorts for the temporal and external validation of the fullPIERS model. The 
decision to use these cohorts in our study was based on the cohorts having similar participant 
inclusion and exclusion criteria, and being derived in a similar tertiary unit health care setting. 
The data included were collected from the (i) British Columbia Women’s (BCW) Hospital (ii) 
the Finnish Genetics of Preeclampsia Consortium (FINNPEC) study (iii) Pre-EcLampsIa: 
Clinical ApplicatioN (PELICAN) of PlGF study (iv) Alere-funded Pre-Eclampsia Triage by 
Rapid Assay (PETRA) study and, (v) John Radcliffe Hospital, Oxford (Oxford).  
The BCW cohort was made up of data extracted from retrospective medical chart reviews for 
women admitted with pre-eclampsia to the BCW’s Hospital (Vancouver, Canada) from January 
2012 to May, 2016. This site was one of the centres involved in the development of the 
fullPIERS model. The FINNPEC study recruited a cross-sectional, case–control cohort of 
singleton pregnancies from five university hospitals in Finland during 2008–2011.13 The 
prospective PELICAN cohort included women who presented with symptoms or signs of 
suspected pre-eclampsia at one consultant-led maternity unit in the UK, January 2011 to 
February 2012.14 The BCW, FINNPEC and PELICAN cohorts centres practised expectant 
management for pre-eclampsia, similar to the centres involved in the development of the 
fullPIERS model. The PETRA cohort included women with symptoms and signs of pre-
eclampsia presenting at twenty-four maternity units in the United States of America (USA) and 
Canada.15 This was a prospective, observational cohort and women were recruited between 
January 2011 and February 2012; however, an interventionist management policy was more 
common in the Alere-PETRA centres. Finally, for the Oxford cohort, data were extracted 
  
 
retrospectively from the hospital flow sheets of women admitted in the Silver Star unit of John 
Radcliffe Hospital, Oxford, from 2003 to 2006. 
For this study we used three sets of validation data: (i) the primary external data, comprising of 
the BCW, FINNPEC, and PELICAN cohorts, (ii) the temporal validation data, comprising of the 
BCW cohort only (iii) and the broader external data comprising of all five cohorts i.e., the BCW, 
FINNPEC, PELICAN, PETRA and Oxford cohorts. We divided the external validation into two 
sections – primary external validation using datasets with similar expectant management policies 
and data collection as that used during fullPIERS model development (to assess the 
reproducibility of the model in the most similar and reliable datasets) and “broader” external 
validation using combined datasets (to assess the overall transportability of the model) due to 
differences in clinical practice and data completeness. We planned a priori to base our 
interpretation of the model performance on the primary external dataset results. In addition, we 
assessed the model in only the BCW cohort for temporal validation because it was one of the 
model development sites.  
Definition of pre-eclampsia and outcomes 
We used the same definitions for pre-eclampsia as used in the fullPIERS model development 
study, as described above. 
The primary outcome in our validation study was also the same as in the model development 
study (Table S1). When the exact time of day of the occurrence of an outcome was unknown, we 
used outcomes occurring within two calendar days from the date of admission as a proxy for 
adverse maternal outcomes occurring within 48 hours. We examined outcomes occurring within 
seven days as a secondary outcome.  
  
 
Statistical analyses 
Demographics 
The distribution of patient characteristics of the five cohorts included in the three validation sets 
were compared with the development (fullPIERS) cohort. Univariate comparisons of 
characteristics of women who experienced an adverse outcome and those who did not, were also 
performed for each validation data set.  
Model performance evaluation 
Using the worst value of each predictor measured within 48 hours of admission prior to the 
occurrence of an adverse outcome, the published fullPIERS equation was applied to each of the 
validation datasets to calculate the predicted probability of experiencing an adverse outcome for 
each woman in the cohort under study. The performance of the model was evaluated based on its 
discrimination, calibration and stratification capacity.  
Discriminative ability was assessed using the AUROC and was interpreted using the following 
pre-specified criteria: non-informative (AUROC ≤ 0·5), poor discrimination (0.5 < AUROC < 
0·7), good discrimination (AUROC ≥ 0·7).7,16 Calibration was assessed by estimating the slope 
on a calibration plot of predicted versus observed outcome rates in each decile of predicted 
probability; a calibration slope of 1 and intercept of 0 is considered ideal.7 Similar to the 
AUROC, a calibration slope was interpreted as: non-informative (slope ≤ 0·5), poor calibration 
(0.5 < slope < 0·7) and good calibration (slope ≥ 0·7).17,18 The stratification capacity of the 
model to classify the women into low- and high- risk categories was assessed using a 
classification table with generated risk groups (defined based on categories established in the 
model development study).17,18 The true and false positive rates, negative predictive values 
  
 
(NPVs), and positive predictive values (PPVs) were computed for each group. The Likelihood 
Ratios (LRs) were calculated for each group using the Deeks and Altman method for a multi-
category diagnostic test.19  
Sensitivity analyses  
For sensitivity analyses, we assessed the model performance in the validation cohorts for the 
prediction of adverse outcomes occurring within seven days of admission as done in the model 
development. This was done to evaluate the model’s clinical utility within a longer time frame. 
Secondary analyses also included assessment of the discrimination capacity of the (i) primary 
and (ii) combined external validation data without the BCW’s Hospital cohort. This was done to 
validate the inclusion of BCW data in all our analyses subsets. 
Missing data  
Missing SpO2 was substituted with the median of 97%, as done during the fullPIERS model 
development.6 If missing, AST was substituted with alanine transaminase (ALT) when available, 
as this measurement had been agreed to be biologically similar by expert opinion. For other 
variables or where both AST and ALT were absent, the type of missingness was explored by 
comparing cases with and without missing data in the validation cohorts, and multiple 
imputations were used to generate plausible values for missing variables. Multiple imputation 
was carried out ten times using the multiple imputation by chained equations (MICE) method.20-
22
  
 
 
  
 
Sample Size 
Our sample size was based on simulation studies which recommend 80-100 events (outcomes) 
and 100 non-events for sufficient power in validation studies.12 This number of events was 
calculated to give 80% power at the 5% significance level. This was used to determine adequate 
statistical power in our study. 
All statistical analyses were performed using R version 3·1·3 (The R Project for Statistical 
Computing). 
RESULTS 
Comparison of the development and validation cohorts 
In total, the combined cohort was made up of 2429 women: BCW (N=1310), FINNPEC 
(N=124), PELICAN (N=70), PETRA (N=644) and Oxford (N=281). The distribution of patient 
characteristics between the development and individual validation cohorts are presented in Table 
1. Compared to the development cohort, the women in the BCW cohort were more likely to be 
older, have a later onset of pre-eclampsia, and higher AST; the FINNPEC cohort was least likely 
to be multiparous and have more symptoms of chest pain or dyspnoea, while the PELICAN 
cohort had the lowest rate of smoking, and higher uric acid measurements. Compared to the 
development cohort, the women in the PETRA cohort were more likely to have an earlier onset 
of pre-eclampsia, had a higher rate of smoking, lower corticosteroid use for early onset pre-
eclampsia but higher use of magnesium sulphate, and shorter admission to delivery for women 
with gestational age less than 34 weeks; they also had lower birth weights. The women in the 
Oxford cohort had higher platelets and creatinine measurements compared to the development 
cohort. 
  
 
The combined distribution of patient characteristics for the cohorts grouped according to their 
analytical use (validation datasets), compared with the development cohort, are presented in 
Table S2. In total, the primary external, temporal validation and broader cohorts included 1504, 
1310, and 2429 women respectively. Compared to the development cohort, the women in the 
primary external datasets were more likely to have an earlier onset of pre-eclampsia and less 
likely to smoke, while the women in the broader external datasets were more likely to 
multiparous and administered MgSO4. The women in both the primary and broader external 
datasets were more likely to be older, compared to the development cohort. 
Within 48 hours of admission, the rates of adverse maternal outcomes encountered in the 
temporal, primary, and broader external validation cohorts were 87 (6.6%), 99 (6.7%) and 171 
(7.0%), respectively. The rates of adverse maternal outcomes occurring within seven days or at 
any time during admission and the rates of stillbirths or neonatal deaths were similar between the 
validation and the development cohorts (Table S2). 
Table S3 presents the individual components of the primary composite adverse outcome that 
occurred within 48 hours of admission. The most common outcomes in combined validation 
cohorts were blood transfusion (N=61), placental abruption (N=21), and infusion of a third 
antihypertensive medication (N=21). There were no cases of maternal deaths, cortical blindness 
or hepatic rupture. 
Women with and without outcomes 
In all the validation cohorts, women with an adverse maternal outcome within 48 hours had an 
earlier onset of pre-eclampsia, worse clinical measures (i.e. higher chest pain, sBP, uric acid, and 
lower platelet count) and more interventions (antihypertensive and magnesium sulphate 
  
 
treatment) (Table S4). They also delivered at an earlier gestational age with babies of lower birth 
weights. These characteristics were similarly observed in the development cohort.6 
Data completeness 
Table S5 shows the number of missing predictor variables in each of the analysis/validation  
cohorts. Gestational age at admission for disease was the most complete variable in all the 
validation datasets except for two missing cases (0.1%) in the broader external dataset while 
chest pain/dyspnoea and SpO2 had the highest proportion of missing data. The broader validation 
dataset had the most missingness overall with 3.3% for platelet count, 4.5% for AST or ALT, 
7.3% for serum creatinine, 37.2% for chest pain or dyspnoea, and 42.4% for SpO2. 
Model performance 
Primary External validation 
The fullPIERS model showed good discrimination in the primary external validation dataset with 
an AUROC of 0.81 (95% CI 0.76-0.87) (Figure 1a). Imputation of missing variables did not 
show any significant change in the discriminatory performance (AUROC of 0.81 (95% CI 0.75-
0.86).  
The model also showed good calibration performance in the primary external validation dataset 
with a slope of 0.70, although the intercept was marginally elevated (α = 0.3) (Figure 2a).  
Table 2 shows the distribution of women in pre-specified predicted probability risk groups and 
the stratification capacity of the model in in each group for the primary external validation 
dataset. The distribution of women in these risk group was similar to the model development 
study with 30.5% of women having a predicted probability of <1% (35% in the development 
  
 
cohort) and 4% of women with a predicted probability of ≥30% (also 4% in the development 
cohort).6 Using the predicted probability cut-off of ≥30% for high risk (pre-identified threshold 
in the model development study), 55% of the women had an adverse outcome. The resulting 
false positive rate was 2% (specificity of 98%) and the true positive rate (sensitivity) was 36% 
with a high LR of 17 (95%CI 10.97-26.43) showing strong evidence to rule in adverse maternal 
outcomes; the LR at the lower predicted scores (<2.5%) were not useful for ruling out adverse 
outcomes. Overall, the model was able to stratify women into a high risk group (predicted 
probability ≥30%) and a low risk group (predicted probability <30%). 
Temporal validation 
For the temporal validation using only the BCW cohort, the fullPIERS model showed good 
discrimination capacity with an AUROC of 0.82 (95% CI 0.76-0.87) (Figure 1c), which did not 
change after imputation of missing values. Calibration was good with a slope of 0.70 and 
intercept of 0.20 (Figure 2b).  
Table 3 presents the distribution of women and the stratification capacity of the model in the 
temporal validation datasets in each pre-specified predicted risk group. The proportions of 
women in the lowest (<1%) and highest risk group (≥30%) were 30% and 5% respectively. The 
proportion of women with adverse outcomes in the highest risk group of ≥0.3 (56%) was also 
similar to the proportion in the development data (59%).6 The resulting false positive rate was 
2% (specificity 98%) and the true positive rate was 41% with a high LR of 18 (95%CI 11.60-
28.16) at this threshold, showing strong evidence to rule in adverse maternal outcomes.  
 
 
  
 
Broader external validation 
The fullPIERS model retained good discrimination in the broader validation dataset although the 
AUROC decreased (0.74 (95% CI 0.69-0.80) (Figure 1c).  As seen in the prior validation 
cohorts, there was also no significant change after imputation of missing data (AUROC of 0.75 
(95% CI 0.71-0.80). Calibration ability was poor with a slope of 0.55 and intercept of 0.30 
(Figure 2c).  
Similar to the primary external validation dataset, about 4% of women had a predicted 
probability of ≥30% (Table 4).6 In this highest risk group, half of women had an adverse 
outcome. The resulting false positive rate was 2% (specificity 98%) and the true positive rate 
was 27% with a LR of 13 (95% CI 9.21-18.9).  
Thus, the LR also showed strong evidence to rule in adverse maternal outcomes in all datasets. 
Sensitivity analyses 
Performance for outcomes within seven days  
Model performance decreased in all three validation datasets for the prediction of adverse 
outcomes within seven days. The AUROCs after imputation of missing data were 0.71 (95% CI 
0.66-0.76), 0.69 (95% CI 0.65-0.73), and 0.78 (95% CI 0.72-0.83), for the primary external, 
broader and temporal validation datasets, respectively. Calibration was poor in all datasets with 
slopes of 0.63, 0.61 and 0.44 for the temporal, primary external and broader external datasets, 
respectively. Similar results were observed from the complete case analyses. 
 
 
  
 
 
Performance of model excluding the BCW cohort 
The discriminatory performance of the model dropped in both the primary and broader external 
validation datasets upon the exclusion of the BCW’s cohort, although the AUROCs remained 
>0.70 (Appendix Figure 1).  
DISCUSSION 
We assessed the temporal and external validation of the fullPIERS model using three datasets 
from high income countries for the prediction of adverse maternal outcomes within 48 hours. 
Overall, the model retained good discriminatory performance across all datasets (AUROC ≥0.7). 
Calibration was good in the primary and temporal external datasets but was poor in the broader 
external dataset, as reflected by the reduction in slope. An increase in the calibration intercept 
was also observed in all three of the validation cohorts. Despite errors in calibration the model 
was able to classify women into low- and high-risk groups using a predicted probability cut-off 
of ≥30% and showed a strong ability to ‘rule in’ adverse outcomes within 48 hours at this cut-
off.  
In external validation studies, decreases in model performance are common and can be a result of 
overfitting of the model to the data used for development, case-mix differences between the 
development and validation cohorts, or differences in the effect of the model predictors between 
the development and validation cohorts, or a combination of some or all of these factors.8 All the 
AUROCs estimated in the three validation cohorts were lower than that estimated in the original 
fullPIERS model development study (0.88 (95% CI 0.84–0.92). This difference was only 
significant in the broader validation cohort (the confidence intervals overlapped for the primary 
  
 
external and temporal validation). A decrease in performance was also observed in the 
calibration ability of the model upon temporal validation, whereby the dataset most similar to the 
development cohort was used. 
There were fewer case-mix differences between the development and temporal validation data 
with regard to demographics, antihypertensive administration, and adverse neonatal and maternal 
outcomes (Table 1). Despite the fact that the women in the temporal cohort had worse predictor 
measurements, the rates of adverse outcomes between the two cohorts were similar, suggesting a 
possible difference in the predictor-outcome relationship. Studies have reported that a slope < 1 
is indicative of inconsistent predictor effects or/and overfitting.7,23 We suspect that it is more 
likely that the reduced performance was due to different predictor effects and perhaps, overfitting 
than due to case-mix differences.9,23  
In addition to the predictor-effects, case-mix differences may have played a more substantial role 
in the broader external dataset, as there were more differences in population characteristics 
observed in the PETRA and Oxford datasets compared to the fulPIERS cohort. There was also a 
slightly higher rate of adverse maternal outcome within 48 hours, which was reflected in the 
calibration intercept (0.3). Of note, the PETRA cohort, which significantly contributed to the 
broader validation dataset, primarily included women admitted in the USA. The pattern of 
practice for the management of women with pre-eclampsia in the USA is different from the other 
datasets in that it is more interventionist than expectant; this could also be observed from the 
short admission to delivery interval for women with gestational age less than 34 weeks compared 
to the other cohorts (Table 1). Earlier delivery would shorten the natural course of pre-eclampsia 
and could reduce performance of the model. The extreme predictions shown in the calibration 
graph (over-prediction of outcomes in the lower risk groups and under-prediction in the higher 
  
 
risk groups) as well as the significant reduction in slope (0.55) are also suggestive of overfitting 
of the model.9 These findings suggest a need for recalibration of the model to improve its 
performance in broader external dataset. 
Comparison with Existing Literature 
Four previous studies have assessed the validity of the fullPIERS model.10,11,24 The study by 
Akkermans et al.24 used a cohort of women with severe, early-onset pre-eclampsia admitted into 
tertiary centres in the Netherlands. Although this study included patients from a similar setting to 
the fullPIERS cohort i.e. tertiary, high income setting, their inclusion criteria may have resulted 
in a significant case-mix difference. In contrast with our study, they reported a higher 
discriminative performance of the model (AUC ROC 0.97, 95% CI: 0.94–0.99). The validation 
studies by Agrawal et al.10 and Ukah et al.11 both examined the fullPIERS model in low 
resourced settings and the study by Hadley et al.25 included women with all HDPs. The use of 
datasets with populations from low-and-middle income settings (less resources and higher rates 
of outcomes), or with different inclusion criteria (e.g. other types of HDPs were included), and 
different management practice (e.g. less expectant management), compared to the development 
cohort, may have also contributed to an increase in severity of case-mix and resulted in the lower 
performance reported by these studies.  Similar to our study; these three studies10,11,25 reported a 
decrease in discriminative ability (although all three studies still reported good discrimination 
AUROC > 0.7).  
Strengths and limitations 
A strength of this study is the assessment of the validity and transportability of the fullPIERS 
risk prediction model using data similar to the model development cohort i.e. data from tertiary 
  
 
and high-income settings. We also had sufficient power to detect any major changes in the model 
performance. The findings from our analyses are important to actually determine if the model 
itself is valid as developed, and not just if it works by chance or due to peculiarities in the 
validation cohort used. The combination of cohorts from different sites also makes our findings 
more generalizable; thus our findings represent a true validation of the model’s performance in 
similar settings.  
One limitation is that to achieve adequate power, we included women from BCW’s Hospital, 
which was one of the development sites, in the primary and broader external validation datasets. 
Although it may be ideal to use completely different sites for an external validation, these 
women were enrolled in a later time period from those used in the development study and can 
still be considered an external cohort. Our sensitivity analyses assessing the impact of including 
the BCW cohort demonstrated that the discriminatory performance without the BCW cohort 
remained good (AUROC >0.70) showing that the model performance was not entirely dependent 
on the BCW cohort.   
Another limitation was the large percentage of missing data in the broader external validation 
dataset. Although we accounted for this limitation by using multiple imputation techniques, these 
may have affected the precision of the model performance estimate. However, research suggests 
that imputation is preferable to omission of individuals, even if a predictor is completely missing 
in a dataset.22,26 Our imputation analyses did not show any significant difference, thereby 
suggesting that there was less likelihood of bias in the broader external datasets. We hope that 
our results will encourage the measurements of SpO2 and other model variables since they are 
important predictors of adverse maternal outcomes within 48 hours. 
  
 
 
Implications for clinical practice  
This external validation study shows that the fullPIERS model is useful in discriminating 
between patients at high and low risk of adverse maternal outcomes within 48 hours and even up 
to a week after assessment. Our study also shows that using a threshold of ≥30% predicted 
probability was a good threshold to rule-in the outcome. Based on our results, the model can be 
used to aid clinicians in managing women with pre-eclampsia in similar settings and to make 
decisions such as transfer to higher care units and delivery. However, caution should be applied 
when using the model in settings with a broader case-mix of patients or a more interventionist 
management style such as those participating in the PETRA study. Recalibration of the model 
should be considered in these settings before clinical use. 
Conclusion 
The fullPIERS model is temporally and externally valid for the prediction of adverse maternal 
outcomes occurring within 48 hours of admission for pre-eclampsia. Recalibration might be 
helpful in improving the calibration performance in more diverse settings. Future studies should 
focus on recalibration and assessing the model performance in broader sub-groups. 
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Table 1. Maternal characteristics for the individual validation datasets and development dataset 
Characteristics fullPIERS 
cohort 
(development) 
 
(2,023 women) 
BCW 
 (1,310 women) 
(Also Temporal) 
FINNPEC 
 (124 women) 
PELICAN 
 (70 women) 
PETRA 
 (644 women) 
Oxford 
(281) 
DEMOGRAPH
ICS & 
PREGNANCY 
CHARACTERI
STICS 
      
Maternal age at 
EDD (yr) 
31 [27, 36] 34 [31, 38] 31 [27, 34] 33 [29, 38] 30 [24, 34] 32 [28, 36] 
Parity ≥1 581 (28·7%) 409 (31.2%) 25 (20.2%) 31 (44.3%) 280 (43.5%) 127 (45.2%) 
Gestational age 
at eligibility 
(wk)** 
36 [33, 38·3] 37.7 [35.6, 39] 35.2 [31.4, 37·0] 35.8 [34.3, 38.0] 33.9 [30.3, 36.3] 36.7 [33.7, 38.3] 
Gestational age 636 (31.4%) 218 (16.6%) 51 (41.1%) 16 (22.9%) 331 (51.4%) 99 (35.2%) 
  
at eligibility <34 
weeks, N 
Multiple 
pregnancy 
192 (9·5%) 136 (10.4%) 0 5 (7.1%) 52 (8.1%) 26 (9.3%) 
Smoking in this 
pregnancy 
249 (12·3%) 90 (6.9%) 15 (12.1%) 2 (2.9%) 140 (21.7%) 23 (8.2%) 
CLINICAL 
MEASURES 
      
Systolic BP 
(mm Hg) 
160 [150, 176] 160 [151, 171] 169 [158, 179] 157 [150, 170] 143 [133, 154] 150 [140, 160] 
Diastolic BP 
(mm Hg) 
102 [98, 110] 100 [94, 105] 104 [99, 110] 98 [92, 102] 84 [76, 93] 98 [90, 101] 
Chest 
pain/dyspnoea*
*  
90 (4.4%) 82 (6.3%) 10 (8.1%) 3 (4.3%) 13 (2.0%) 7 (2.5%) 
Uric acid 376 [320, 427] 379 [323, 436] 366 [323, 423] 400 [325, 495] 369 [309, 428] 337 [271, 390] 
  
(µM)  
Lowest platelet 
count 
(×10
9
 per L)** 
192 [150, 242] 174 [136, 217] 187 [153, 232] 170 [128, 212] 203 [158, 248] 225 [178, 275] 
Highest 
AST/ALT 
(U/L)** 
28 [21, 41] 33 [26, 47] 19 [14, 30] 20 [14, 32] 23 [18, 34] 17 [13, 27] 
Creatinine 
(µM) 
67 [58, 77] 64 [56, 75] 62 [54, 69] 70 [59, 84] 61 [53, 71] 75 [68, 84] 
INTERVENTI
ONS DURING 
ADMISSION 
      
Corticosteroids 550 (27·2%) 320 (24.4%) 56 (45.2%) 31 (44.3%) 161 (25.0%) 78 (27.8%) 
Corticosteroids, 
GA onset <34 
440/636 (69.2%) 195/218 (89.5%) 43/51 (84.3%) 14/16 (87.5%) 137/331 (41.4%) 65/99 (65.7%) 
Antihypertensiv 1381 (68·3%) 896 (68.4%) 104 (83.9%) 58 (82.9%) 463 (71.9%) 175 (62.3%) 
  
e therapy 
MgSO4  690 (34·1%) 393 (30.0%) 69 (55.7%) 11 (15.7%) 464 (72.1%) 31 (11.0%) 
PREGNANCY 
OUTCOMES 
      
Admission-To-
Delivery 
Interval (Days) 
2 [1, 5] 1 [1, 3] 4 [2, 7] 6 [3, 14] 2 [1, 4] 3 [1, 8] 
Admission-To-
Delivery 
Interval, <34⁺⁰ 
Weeks (Days) 
4 [2, 14] 4 [2, 11] 6 [3, 8] 13 [8, 26] 3 [1, 6] 8 [4, 19] 
Gestational age 
at delivery (wk) 
36.9 [34·1, 38·6] 37.8 [36, 39.1] 35.9 [32.3, 37.9] 37.6 [36.3, 38.3] 34.6 [31.1, 36.9] 36.7 [33.7, 38.3] 
Birth weight 
(grams) 
2141  
[1441, 2807] 
2885  
[2275, 3364] 
2305  
[1475, 2930] 
2700  
[2065, 3150] 
2070  
[1286, 2770] 
2516  
[1647, 3216] 
Stillbirth 20 (1.0%) 7 (0.5%) 0  0 10 (1.6%) 8 (2.9%) 
  
Neonatal death 26 (1·3%) 10 (0.8%) 1 (0.8%) 0  13 (2.0%) 25 (8.9%) 
MATERNAL 
OUTCOME  
(N women) 
      
Within 48h 106 (5.2%) 87 (6.6%) 11 (8.9%) 1 (1.4%) 48 (7.5%) 24 (8.5%) 
Within 7 days 203 (10.0%) 110 (8.4%) 40 (32.3%) 2 (2.9%) 56 (8.7%) 45 (16.0%) 
At anytime 261 (12.9%) 122 (9.3%) 62 (50.0%) 6 (8.6%) 62 (9.6%) 57 (20.3%) 
       
AST (aspartate aminotransferase), BP (blood pressure), EDD (estimated date of delivery), MgSO4 (magnesium sulphate) 
** Variables included in the model  
 
 
  
 
Table 2. Risk stratification table to assess the performance of the fullPIERS model for predicting 
maternal outcome at varying predicted probability cut-off values within 48h in the Primary 
External Validation dataset. 
Prediction 
score range 
(Mean 
predicted 
probability) 
Total N 
women in 
range (%) 
(N=1504) 
N women 
with 
outcome 
(%) 
(N=99) 
LR 
[95% 
CI] 
NPV 
(%) 
[95% 
CI] 
PPV 
(%) 
 [95% 
CI] 
*True 
positive 
rate (%) 
[95% 
CI] 
False 
positive 
rate (%) 
[95% CI] 
<1.0% 
(0.5%) 
459 
(30.5%) 
8 (1.7%)  0·25  
[0·12-
0.52]  
- - - - 
 
1·0-2·4% 
(1.2%) 
498 
(33.1%) 
14 (2.8%)  0·41 
[0·25-
0.67] 
98 
[0·96-
0·99] 
8.6 
[0·07-
0·11] 
92 
[0·84- 
0·96] 
68 
[0·65-
0·70] 
2·5-4·9% 
(3.4%) 
287 
(19.1%) 
13 (4.5%)  0·67 
[0·40-
1.13] 
98 
[0·96-
0·99] 
14 
[0·11-
0·17] 
78 
[0·68-
0·85] 
34 
[0·31- 
0·40] 
5·0-9·9% 
(7.0%) 
117 (7.8%) 16 
(13.7%)  
2.25 
[1.38-
3.66] 
97 
[0·96-
0·98] 
25 
[0·20-
0·31] 
65 
[0·54-
0·74] 
14 
[0·12-
0·16] 
10·0-29·9% 
(17.2%) 
77 (5.1%) 12 
(15.6%) 
2.62 
[1.47-
4.68] 
96 
[0·95-
0·97] 
47 
[0·36-
0·58] 
41 
[0·32-
0·52] 
7 
[0·06-
0·08] 
≥30·0% 
(60.9%) 
66 (4.4%) 36 
(54.5%) 
17.03 
[10.97-
26.43] 
96 
[0·94-
0·97] 
55 
[0·42-
0·67] 
36 
[0·27-
0·47] 
2 
[0·02-
0·03] 
        
LR, Likelihood ratios; PPV, positive predictive value; NPV, negative predictive value.  
*True positive rate (or Sensitivity), false positive rate (1-Specificity)  
 
 
 
Table 3. Risk stratification table to assess the performance of the fullPIERS model for predicting 
maternal outcome at varying predicted probability cut-off values within 48h in the temporal 
dataset 
  
 
Prediction 
score 
range 
Total N 
women in 
range (%) 
(N=1310 ) 
N women 
with 
outcome 
(%) 
(N= 87) 
LR 
[95% CI] 
NPV 
(%) 
[95% 
CI] 
PPV 
(%) 
 [95% 
CI] 
*True 
positive 
rate (%) 
[95% 
CI] 
False 
positive 
rate (%) 
[95% CI] 
<1.0% 
(0.6%) 
395 
(30.2%) 
6 (1.5%)  
 
0·22  
[0·09-
0·50]  
- - - - 
1·0-2·4% 
(1.2%) 
430 
(32.8%) 
11 (2.6%)  0·37 
[0·21-
0·64] 
98 
[0·97-
0·99] 
8.9 
[0·07-
0·11] 
93 
[0·85- 
0·97] 
68 
[0·66-
0·70] 
2·5-4·9% 
(3.4%) 
247 
(18.9%) 
11 (4.5%)  0·66 
[0·37-
1.51] 
98 
[0·97-
0·99] 
14 
[0·12-
0·18] 
80 
[0·70-
0·88] 
34 
[0·31- 
0·37] 
5·0-9·9% 
(7.0%) 
109 (8.3%) 14 (12.8%)  2.07 
[1.24-
3.47] 
97 
[0·96-
0·98] 
25 
[0·20-
0·31] 
68 
[0·57-
0·77] 
15 
[0·13-
0·17] 
10·0-
29·9% 
(16.9%) 
65 (5.0%) 9 (13.8%) 2.26 
[1.16-
4.41] 
96 
[0·95-
0·97] 
48 
[0·37-
0·59] 
45 
[0·34-
0·56] 
7 
[0·06-
0·08] 
≥30·0% 
(61.5%) 
64 (4.9%) 36 (56.3%) 18.07 
[11.60-
28·16] 
96 
[0·95-
0·97] 
56 
[0·43-
0·68] 
41 
[0·31-
0·52] 
2 
[0·02-
0·03] 
        
LR, Likelihood ratios; PPV, positive predictive value; NPV, negative predictive value.  
*True positive rate (or Sensitivity), false positive rate (1-Specificity)  
 
 
 
Table 4. Risk stratification table to assess the performance of the fullPIERS model for predicting 
maternal outcome at varying predicted probability cut-off values within 48h in the Broader 
(Combined) dataset. 
Prediction Total N 
women in 
range (%) 
N women 
with 
outcome 
LR NPV PPV *True False 
  
 
score 
range 
(N=2,429) (%) 
(N=171) 
[95% 
CI] 
(%) 
[95% 
CI] 
(%) 
 [95% 
CI] 
positive 
rate (%) 
[95% 
CI] 
positive 
rate (%) 
[95% CI] 
<1% 
(0.6%) 
604 
(24.9%) 
14 (2.3%)  0·31  
[0·18-
0·55]  
- - - - 
 
1·0-2·4% 
(1.7%) 
779 
(32.1%) 
27 (3.5%)  0·47 
[0·34-
0·66] 
98 
[0·96-
0·99] 
8.6 
[0·07-
0·10] 
92 
[0·86- 
0·95] 
74 
[0·72-
0·76] 
2·5-4·9% 
(3.5%) 
526 
(21.7%) 
31 (5.9%)  0·83 
[0·61-
1.12] 
97 
[0·96-
0·99] 
12 
[0·11-
0·15] 
76 
[0·69-
0·82] 
41 
[0·39- 
0·43] 
5·0-9·9% 
(7.0%) 
259 
(10.7%) 
30 
(11.6%)  
1.73 
[1.25-
2.40] 
96 
[0·95-
0·97] 
19 
[0·16-
0·23] 
58 
[0·50-
0·65] 
19 
[0·17-
0·20] 
10·0-
29·9% 
(16.3%) 
169 (7.0%) 23 
(13.6%) 
2.08 
[1.40-
2.09] 
95 
[0·94-
0·96] 
26 
[0·21-
0·32] 
40 
[0·33-
0·48] 
9 
[0·07-
0·10] 
≥30·0% 
(60.4%) 
92 (3.8%) 46 
(50.0%) 
13.20 
[9.21-
18.9] 
95 
[0·94-
0·96] 
50 
[0·39-
0·61] 
27 
[0·21-
0·34 
2 
[0·02-
0·03] 
        
LR, Likelihood ratios; PPV, positive predictive value; NPV, negative predictive value.  
*True positive rate (or Sensitivity), false positive rate (1-Specificity)  
 
 
  
  
  
 
   
A) Primary external dataset                                         B) Temporal dataset                    
 
 
C) Broader external dataset                                         
Figure1. Discriminatory performance in A) Primary external, B) Temporal dataset and C) 
Broader external datasets for adverse maternal outcomes occurring within 48hrs of admission 
  
  
 
 
 
(A) Primary external                                                                         (B) Temporal           
 
  
 
(C) Broader  
Figure 2. Calibration graphs for the (A) Primary external (B) Temporal and (C) Broader 
validation datasets for adverse maternal outcomes occurring within 48hrs of admission 
  
  
 
HIGHLIGHTS 
• Hypertension in pregnancy contributes to maternal morbidity and mortality  
• The fullPIERS model was developed for predicting maternal adverse outcomes from pre-
eclampsia  
• The fullPIERS model is externally and temporally valid 
• The model will aid in preventing severe maternal complications through early 
identification.  
• This study shows that the fullPIERS model could aid in reducing the global burden of 
HDPs. 
 
 
 
 
 
 
